TY  - JOUR

T1  - Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).

JO  - European Journal of Cancer

PY  - 2013/06/24

AU  - O'Brien ME

AU  - Gafaar RM

AU  - Popat S

AU  - Grossi F

AU  - Price A

AU  - Talbot DC

AU  - Cufer T

AU  - Ottensmeier C

AU  - Danson S

AU  - Pallis A

AU  - Hasan B et al

ED  - 

DO  - DOI: 10.1016/j.ejca.2013.05.008

Y2  - 2024/09/19

ER  -